ArriVent Announces a Multi-Target ADC Collaboration with Alphamab
Collaboration will leverage Alphamab’s antibody drug conjugate (“ADC”) research and discovery platform and ArriVent’s global development and commercialization expertise Upfront and milestone...
NEWTON SQUARE, Pa., May 16, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics,...
NEWTON SQUARE, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical...
Consider that IPO window well and truly opened. The day after CG Oncology became the first biotech to join the Nasdaq in 2024, ArriVent BioPharma has now followed suit with its own upsized offering.
ArriVent Announces Pricing of Upsized Initial Public Offering
Arrivent's price per common stock share is expected to be between $17 and $19. (AndreyPopov/iStock/Getty Images Plus)nAs one of the first in a new year wave of biotechs to announce IPO plans, Arrivent Biopharma has now said it expects to raise around $135 million in the company’s upcoming public offering.
Seems the IPO window is open at least a crack, and Metagenomi is ready to sneak through with Arrivent Biopharma hot on its tail.
ArriVent Appoints Winston Kung as Chief Financial Officer and Treasurer
Pennsylvania oncology drugmaker ArriVent Biopharma has filed for an initial public offering, making it the second biotech to reveal its plans for a Nasdaq listing this year so far.